BioNTech (BNTX) investor relations material

Executive summary

• Appointed Guido Oelkers, Ph.D., as incoming CEO, effective by February 1, 2027, to lead the next phase of growth, and expanded the Supervisory Board with two new members.

• Transition reflects a shift from research-focused to global commercial organization, with a robust late-stage oncology pipeline and pivotal trials.

• Advanced pipeline with 14 ongoing pivotal clinical trials and over ten novel combinations in major tumor types.

• Achieved multiple 2026 milestones, including six pivotal trial initiations and regulatory approval for a new COVID-19 vaccine variant.

• Disciplined cost management in response to lower COVID-19 vaccine demand, with continued prioritization of R&D in oncology.

Financial highlights

• Q2 2026 revenues were €105.6 million, down from €261 million year-over-year, mainly due to lower COVID-19 vaccine demand and absence of prior year one-time revenue.

• Net loss for Q2 2026 was €820.8 million (diluted loss per share: €3.24), compared to €386.6 million in Q2 2025.

• Adjusted R&D expenses for Q2 2026 were €477.1 million; adjusted SG&A expenses were €197.8 million.

• Cash, cash equivalents, and security investments totaled €16.6 billion as of June 30, 2026.

• H1 2026 revenues were €224 million, with lower R&D expenses and higher SG&A compared to prior year.

Outlook and guidance

• Revised 2026 revenue guidance to €1.6–1.9 billion, down from €2.0–2.3 billion, due to softer COVID-19 vaccine demand and delayed milestone revenues.

• Adjusted R&D expense guidance lowered to €2.0–2.3 billion; SG&A guidance maintained at €700–800 million.

• Majority of 2026 revenues expected in H2, with significant BMS collaboration revenue recognized in Q3.